These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9113)

  • 1. [Changes in drug elimination under the influence of perazine therapy (author's transl)].
    Petruch F; Schüppel R; Breyer U
    Arzneimittelforschung; 1976; 26(6):1154-5. PubMed ID: 9113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
    Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
    Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data.
    Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E
    Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings: Effect of chronic treatment with perazine (Taxilan-R) on the pharmacokinetic behaviour of phenazone in man.
    Schüppel RV; Petruch F
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R90. PubMed ID: 238154
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of metronidazole on phenazone metabolism].
    Staiger C; Wang NS; de Vries J; Weber E
    Arzneimittelforschung; 1984; 34(1):89-91. PubMed ID: 6538427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution interactions between perazine and antidepressant drugs. In vivo studies.
    Wójcikowski J; Daniel WA
    Pol J Pharmacol; 2000; 52(6):449-57. PubMed ID: 11334238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
    Wiela-Hojenska A; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Kotlarek-Haus S; Hurkacz M
    Int J Clin Pharmacol Ther; 1999 May; 37(5):234-7. PubMed ID: 10363621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine.
    Daniel WA; Syrek M; Haduch A; Wójcikowski J
    Pol J Pharmacol; 1998; 50(6):431-42. PubMed ID: 10385926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.
    Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
    Eur Neuropsychopharmacol; 2004 May; 14(3):199-208. PubMed ID: 15056479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
    Eichelbaum M; Ochs HR; Roberts G; Somogyi A
    Arzneimittelforschung; 1982; 32(5):575-8. PubMed ID: 7201837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological studies on perazine and its primary metabolites.
    Brand U; Menge HG; Neumann BW; Stille G
    Pharmacopsychiatry; 1989 Nov; 22(6):255-7. PubMed ID: 2575764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specific binding of perazine, a piperazine side-chain phenothiazine drug, to a serum protein (author's transl)].
    Schley J; Nündel M; Riedel E; Müller-Oerlinghausen B
    Arzneimittelforschung; 1979; 29(1):106-8. PubMed ID: 36101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
    Janus K; Baranow-Baranowski S; Jakubowska D
    Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenazone pharmacokinetics as an index of hepatic metabolic efficiency.
    Wiela A; Orzechowska-Juzwenko K; Kotlarek-Haus S; Plamieniak B; Wolowiec D
    Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):562-5. PubMed ID: 3243660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.
    Pietzcker A; Poppenberg A; Schley J; Müller-Oerlinghausen B
    Arch Psychiatr Nervenkr (1970); 1981; 229(4):315-29. PubMed ID: 6111989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thin-layer chromatographic determination of plasma levels of tricyclic psychopharmacological drugs: first results on their relationship to the clinical activity of neuroleptics (author's transl)].
    Breyer U; Petruch F; Gaertner HJ; Pflug B
    Arzneimittelforschung; 1976; 26(6):1153. PubMed ID: 989405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
    Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the capacity of the liver for phenazone biotransformation in patients with uremia on peritoneal dialysis].
    Grzegorzewska A; Lowicki Z; Chmara E; Mrozikiewicz A; Baczyk K
    Pol Tyg Lek; 1990 Apr 16-30; 45(16-18):339-41. PubMed ID: 2235722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of schistosomiasis infection on the clearance of phenazone in mice.
    Metwally AA; Janku I; Kemper F; Khayyal MT; Ebeid FA; Botros SS
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):206-9. PubMed ID: 2110459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.